Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Bulletin Du Cancer|May 19, 2005
[Cyclooxygenase 2 inhibitors and lung carcinoma]Jean-Philippe Spano, Kader Chouahnia, Jean-François Morère
Bulletin Du Cancer|July 9, 2004
[Cyclooxygenase 2 inhibitors and lung carcinoma]Jean-Philippe Spano, Kader Chouahnia, Jean-François Morère
Bulletin Du Cancer|May 19, 2005
[Cardiovascular toxicity of some cancer agents (others than anthracyclines, fluoropyrimidines and trastuzumab)]Pierre Saintigny, Kader Chouahnia, Jean-Christophe Charniot, et al.
Targeted Oncology|November 26, 2011
Cardiovascular toxicity of anti-angiogenic drugsGaetan des Guetz, Bernard Uzzan, Kader Chouahnia, et al.
Plos One|December 17, 2015
18F-FDG PET-Derived Textural Indices Reflect Tissue-Specific Uptake Pattern in Non-Small Cell Lung CancerFanny Orlhac, Michaël Soussan, Kader Chouahnia, et al.
EJNMMI Research|January 30, 2019
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCISTLucas Goldfarb, Boris Duchemann, Kader Chouahnia, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Drugs & Aging|July 19, 2020
Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-AnalysisThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Journal of Cancer Research and Clinical Oncology|November 6, 2019
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancersThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Targeted Oncology|June 21, 2015
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-AnalysisGaetan Des Guetz, Thierry Landre, Bernard Uzzan, et al.
Pageof 4